| Title |
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders
|
|---|---|
| Published in |
Vascular Health and Risk Management, November 2016
|
| DOI | 10.2147/vhrm.s83719 |
| Pubmed ID | |
| Authors |
Sanjiv Gupta |
| Abstract |
The aim of this manuscript is to review available data to evaluate the present status of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia. Relevant literature since 2003 is reviewed. The effectiveness of PCSK9 inhibitors in lowering low-density lipoprotein cholesterol and other atherogenic lipid fractions was studied in various Phase 2 and Phase 3 trials of Alirocumab, Evolocumab, and Bococizumab. The results of published long-term ODYSSEY and OSLER studies are summarized. There have been three excellent meta-analysis studies on PCSK9 inhibitors which are outlined. The complex problem of cost-effectiveness was carefully evaluated by the Institute for Clinical and Economic Review (ICER). The draft report (ICER-2015) is summarized herewith. The cardiovascular outcome trials with Evolocumab (FOURIER), Alirocumab (ODYSSEY OUTCOME) and Bococizumab (SPIRE-1 and SPIRE-2) are the ongoing clinical trials, and their results are expected in 2017-2018. The search for new cost-effective analogs of PCSK9 inhibitors is ongoing. |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 2% |
| Netherlands | 1 | 2% |
| France | 1 | 2% |
| Unknown | 46 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 12% |
| Student > Master | 6 | 12% |
| Student > Bachelor | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Doctoral Student | 4 | 8% |
| Other | 11 | 22% |
| Unknown | 11 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 12% |
| Nursing and Health Professions | 4 | 8% |
| Agricultural and Biological Sciences | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Other | 3 | 6% |
| Unknown | 14 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 May 2017.
All research outputs
#8,262,445
of 25,374,917 outputs
Outputs from Vascular Health and Risk Management
#284
of 804 outputs
Outputs of similar age
#114,763
of 317,812 outputs
Outputs of similar age from Vascular Health and Risk Management
#5
of 11 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,812 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.